NASDAQ:PHIO 3 November 2025 - 11 February 2026

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technologyphiopharma.com. Originally known as RXi Pharmaceuticals, Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancerragingbull.com.